Want to see RBOT full AI Analyst Report?
RBOT Stock Chart & Stats
$1.82
-$0.68(-4.53%)
At close: 4:00 PM EST
$1.82
-$0.68(-4.53%)
Day’s Range― - ―
52-Week Range$0.14 - $13.75
Previous CloseN/A
Volume30.88K
Average Volume (3M)90.39K
Market Cap
$1.32M
Enterprise Value$7.32M
Total Cash (Recent Filing)$3.68M
Total Debt (Recent Filing)$7.20M
Price to Earnings (P/E)―
Beta2.36
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.75
Shares Outstanding6,477,365
10 Day Avg. Volume138,739
30 Day Avg. Volume90,387
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.31
Price to Sales (P/S)0.00
P/FCF Ratio-0.29
Enterprise Value/Market Cap5.56
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-8.86
Enterprise Value/Ebitda-0.18
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4.07
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercialization MilestoneTarget to deliver a design-frozen, production-equivalent system with required commercialization features by year-end 2026 could materially de-risk the path to market.
Risk-reducing Execution ShiftRefocusing on achieving design freeze rather than pursuing an earlier clinical start reduces technical and regulatory execution risk and clarifies operational priorities.
Strategic OutsourcingPlanned partnership with a consultant to outsource certain components aims to reduce cash burn and sharpen focus on proprietary technology development.
Bears Say
Analyst SentimentAnalyst's neutral recommendation reflects delays in product development and a challenging macroeconomic backdrop, suggesting investors may prefer to wait for clearer progress.
Capital Runway RiskAnalysts warn the company may exhaust cash by early fiscal 2026 without significant cuts to cash burn or new financing, creating funding pressure for continued development.
Extended Development TimelineDesign freeze timeline extended to the end of fiscal 2026 from a mid-fiscal 2026 target, increasing uncertainty on product readiness and launch timing.
Vicarious Surgical News
RBOT FAQ
What was Vicarious Surgical’s price range in the past 12 months?
Vicarious Surgical lowest stock price was $0.14 and its highest was $13.75 in the past 12 months.
What is Vicarious Surgical’s market cap?
Vicarious Surgical’s market cap is $1.32M.
When is Vicarious Surgical’s upcoming earnings report date?
Vicarious Surgical’s upcoming earnings report date is Aug 18, 2026 which is in 43 days.
How were Vicarious Surgical’s earnings last quarter?
Vicarious Surgical released its earnings results on Apr 30, 2026. The company reported -$1.03 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.03.
Is Vicarious Surgical overvalued?
According to Wall Street analysts Vicarious Surgical’s price is currently Overvalued.
Does Vicarious Surgical pay dividends?
Vicarious Surgical does not currently pay dividends.
What is Vicarious Surgical’s EPS estimate?
Vicarious Surgical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vicarious Surgical have?
Vicarious Surgical has 6,477,365 shares outstanding.
What happened to Vicarious Surgical’s price movement after its last earnings report?
Vicarious Surgical reported an EPS of -$1.03 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.091%.
Which hedge fund is a major shareholder of Vicarious Surgical?
Currently, no hedge funds are holding shares in RBOT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vicarious Surgical
Vicarious Surgical Inc. is dedicated to the development and commercialization of advanced single-incision surgical robotics. Their innovative technology is designed to give surgeons a virtual, immersive presence within the patient's body, facilitating highly precise and minimally invasive operations. The company's primary product, the Vicarious System, is a sophisticated single-incision robot engineered specifically for procedures like ventral hernia repair. Established in 2014, Vicarious Surgical Inc. operates from its corporate headquarters in Waltham, Massachusetts.
Technical Analysis
LivaNova
―
Xtant Medical Holdings
―
Inspire Medical Systems
―
Outset Medical
―
PROCEPT BioRobotics
―
Ownership Overview
11.50% Insiders
0.95% Mutual Funds
1.39% Other Institutional Investors
85.85% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---